BridgeBio Pharma, Inc. BBIO
Set alert
75.00 USD +0.05 +0.06%
At close · Nov 2
74.25 -0.75 -0.99%
After hours · Nov 2, 4:00 PM ET
74.20 Day range 76.70
60.22 52-week range 93.42
- YTD
- -1.95%
- 1 year
- +19.72%
- Open
- 74.96
- Prev close
- 74.95
- Mkt cap
- 14.61B
- Vol
- 3.10M
- Avg vol
- 2.57M
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 74.20
- High
- 76.70
- Forward P/E
- -231.49
- Beta
- 0.94
- Short ratio
- 6.50
- Inst. own
- 99.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 70.27
- 200-d avg
- 72.74
- 1y target
- 107.11
3M chart
Events in this range
- Aug 10, 2026Earnings: -0.78; estimate -0.57558; surprise -35.52%
- Oct 19, 2026Rating: Piper Sandler · Overweight → Overweight
- Oct 19, 2026Rating: Citigroup · Neutral → Neutral
- Oct 21, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 29, 2026Earnings: -0.42; estimate -0.54225; surprise 22.54%
- Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
- Nov 2, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (10)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
Financial health
Altman Z-Score
-0.07 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -20.2×
FY 2017 5y median -9.5× FY 2025
P/S 30.0×
FY 2017 5y median 30.0× FY 2025
P/B -7.3×
FY 2017 5y median -3.5× FY 2025
P/FCF -33.8×
FY 2017 5y median -9.8× FY 2025
EV/EBITDA -25.5×
FY 2017 5y median -14.0× FY 2025
EV/Sales 34.3×
FY 2017 5y median 34.3× FY 2025
FCF Yield -3.0%
FY 2017 5y median -10.2% FY 2025
Profitability
Gross Margin 94.4%
FY 2017 5y median 95.5% FY 2025
Operating Margin -113.3%
FY 2017 5y median -659.6% FY 2025
Net Margin -145.3%
FY 2017 5y median -619.7% FY 2025
ROE 35.1%
FY 2017 5y median 38.4% FY 2025
ROIC -108.5%
FY 2017 5y median -101.4% FY 2025
ROA -77.9%
FY 2017 5y median -77.2% FY 2025
Growth (YoY)
Revenue 126.3%
FY 2017 FY 2025
Operating Income 4.0%
FY 2017 FY 2025
EPS (diluted) -31.6%
FY 2017 FY 2025
Free Cash Flow 14.3%
FY 2017 FY 2025
Financial Health
Current Ratio 2.6×
FY 2017 5y median 4.5× FY 2025
Quick Ratio 2.5×
FY 2017 5y median 4.5× FY 2025
Debt / Equity -1.3×
FY 2017 5y median -1.3× FY 2025
Net Debt / EBITDA -3.2×
FY 2017 5y median -2.5× FY 2025
Interest Coverage -10.7×
FY 2017 5y median -7.5× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
